0001213660
false
0001213660
2023-10-30
2023-10-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 30, 2023
BIMI International Medical Inc. |
(Exact name of registrant as specified in its charter) |
Delaware |
|
001-34890 |
|
02-0563302 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
725 5th Avenue, 15th Floor, 15-01
New York NY |
|
10022 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: 212 542 0028
|
(Former name or former address, if changed since last report) |
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common stock, $0.001 par value |
|
BIMI |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On October 30, 2023, BIMI International Medical Inc. (the “Company”
or the “Registrant”) issued two press releases. The first press release announced the appointment by its subsidiary, Phenix
Bio Inc. (“Phenix”), of Hao Mu Pte. Ltd. (“Hao Mu”), a Singapore company, as its non-exclusive distributor for
its 17 herbal supplements in Mainland China. A copy of this press release is filed herewith as Exhibit 99.1 and is incorporated herein
by reference.
The second press release announced Phenix’s appointment of Hao
Mu as its exclusive distributor for its herbal supplements in Hong Kong, Taiwan, and Macau. A copy of this press release is filed herewith
as Exhibit 99.2 and is incorporated herein by reference.
Item 9.01. Financial Statement and Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: October 30, 2023 |
BIMI International Medical Inc. |
|
|
|
By: |
/s/ Tiewei Song |
|
Name: |
Tiewei Song |
|
Title: |
Chief Executive Officer |
Exhibit 99.1
BIMI International Medical Inc. Announces Subsidiary Phenix Bio
Inc’s Appointment of Mainland China Non-Exclusive Distributor
NEW YORK,
NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”),
a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore
company (“Hao Mu”), as a distributor responsible for the distribution of Phenix’s
17 herbal supplements in Mainland China.
Pursuant to the terms of a sales agreement entered into on October
29, 2023, Hao Mu must make annual purchases of at least $5 million in order to maintain its distributor status for this territory.
Under the terms of this agreement, Phenix’s
comprehensive portfolio of high-quality herbal supplements will be made available to consumers in Mainland China through Hao Mu’s
well-established distribution channels and network.
“Expanding
our partnership with Hao Mu to Mainland China shows our faith in Hao Mu and its ability to make our products available to wider markets”
stated Tiewei Song, CEO of BIMI.
This extension of its partnership with Hao Mu evidences BIMI’s
commitment to deliver world-class healthcare solutions and services to a broader global audience. Representatives from BIMI, Phenix, and
Hao Mu, including BIMI’s Chief of Staff, Mr. Symington Smith, and
Hao Mu’s Chief Executive Officer, Mr. Liu Yubao, attended a signing
ceremony held at BIMI’s headquarters in New York City.
About BIMI International Medical Inc.
BIMI International Medical Inc. is a healthcare products and services
provider, offering a broad range of healthcare products and related services in the U.S. and Asia. For more information, please visit
www.usbimi.com.
About Hao Mu Pte. Ltd
Hao Mu Pte Ltd is a service and distribution company in Singapore with
a strong market presence within the ASEAN region. It is dedicated to offering top-quality products and services.
Safe Harbor Statement
Certain matters discussed in this news release are forward-looking
statements that involve a number of risks and uncertainties including, but not limited to, the Company’s
ability to achieve profitable operations, its ability to continue to operate as a going concern, its ability to continue to meet NASDAQ
continued listing requirements, the effects of the spread of COVID-19, the demand for the Company’s
products and services, general economic conditions and other risk factors detailed in the Company’s
annual report and other filings with the United States Securities and Exchange Commission.
Investor Relations Contact
Investor Relations Department of BIMI International Medical Inc.
Email: vinson@usbimi.com
Tel: +1 949 981 6274
Exhibit 99.2
BIMI International Medical Inc. Announces Subsidiary Phenix Bio
Inc’s Appointment of Hong Kong, Taiwan, and Macau Exclusive Distributor
NEW YORK, NY, Oct. 30, 2023 — BIMI International Medical
Inc. (NASDAQ: BIMI, “BIMI”), a healthcare products and services
provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company (“Hao Mu”),
as its exclusive distributor responsible for the distribution of Phenix’s
17 herbal supplements in Hong Kong, Taiwan and Macau.
Pursuant to the terms of a sales agreement entered into on October
29, 2023, Hao Mu must make annual purchases of at least $5 million in order to maintain its exclusive distributor status for this territory.
Under the terms of this agreement, Phenix’s
comprehensive portfolio of high-quality herbal supplements will be made available to consumers in Hong Kong, Taiwan and Macau through
Hao Mu’s well-established distribution channels and network.
“We
are excited to extend our agreement with Hao Mu,” stated Tiewei Song, CEO of BIMI. “Expanding
our cooperation with Hao Mu will allow us to materialize our vision of making top-tier herbal supplements accessible to individuals throughout
Hong Kong, Taiwan and Macau.”
This extension of its partnership with Hao Mu evidences BIMI’s
commitment to deliver world-class healthcare solutions and services to a broader global audience. Representatives from BIMI, Phenix, and
Hao Mu, including BIMI’s Chief of Staff, Mr. Symington Smith, and
Hao Mu’s Chief Executive Officer, Mr. Liu Yubao, attended a signing
ceremony held at BIMI’s headquarters in New York City.
Hao Mu was previously appointed as Phenix’s exclusive
distributor for the ten-member ASEAN countries. If Hao Mu is successful in meeting its minimum annual purchase of $5 million for
each of its three territories, the ten-member ASEAN countries, Mainland China, and Hong Kong, Taiwan and Macao, it will result in
minimum annual sales of $15 million or minimum aggregate sales of $75 million for the next five years of Phenix’s herbal
supplements. No assurance can be given that Hao Mu will be successful in reaching these annual minimums.
About BIMI International Medical Inc.
BIMI International Medical Inc. is a healthcare products and services
provider, offering a broad range of healthcare products and related services in the U.S. and Asia. For more information, please visit
www.usbimi.com.
About Hao Mu Pte. Ltd
Hao Mu Pte Ltd is a service and distribution company in Singapore with
a strong market presence within the ASEAN region. It is dedicated to offering top-quality products and services.
Safe Harbor Statement
Certain matters discussed in this news release are forward-looking
statements that involve a number of risks and uncertainties including, but not limited to, the Company’s
ability to achieve profitable operations, its ability to continue to operate as a going concern, its ability to continue to meet NASDAQ
continued listing requirements, the effects of the spread of COVID-19, the demand for the Company’s
products and services, general economic conditions and other risk factors detailed in the Company’s
annual report and other filings with the United States Securities and Exchange Commission.
Investor Relations Contact
Investor Relations Department of BIMI International Medical Inc.
Email: vinson@usbimi.com
Tel: +1 949 981 6274
v3.23.3
Cover
|
Oct. 30, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Oct. 30, 2023
|
Entity File Number |
001-34890
|
Entity Registrant Name |
BIMI International Medical Inc.
|
Entity Central Index Key |
0001213660
|
Entity Tax Identification Number |
02-0563302
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
725 5th Avenue
|
Entity Address, Address Line Two |
15th Floor
|
Entity Address, Address Line Three |
15-01
|
Entity Address, City or Town |
New York
|
Entity Address, State or Province |
NY
|
Entity Address, Postal Zip Code |
10022
|
City Area Code |
212
|
Local Phone Number |
542 0028
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common stock, $0.001 par value
|
Trading Symbol |
BIMI
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 3 such as an Office Park
+ References
+ Details
Name: |
dei_EntityAddressAddressLine3 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
BIMI International Medical (NASDAQ:BIMI)
過去 株価チャート
から 5 2024 まで 6 2024
BIMI International Medical (NASDAQ:BIMI)
過去 株価チャート
から 6 2023 まで 6 2024